Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04044859
Title ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Adaptimmune
Age Groups: adult | senior
Covered Countries USA | ESP | CAN | BEL

No variant requirements are available.